{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:16:57Z","timestamp":1768079817606,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":461,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anders Wikl\u00f6f"},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In patients with heart failure, treatment patterns in the last years of life have not been assessed at large scale. We aimed to assess whether heart failure treatment patterns up to 5\u2009years prior to death changed over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In a cohort study covering the whole Swedish population, we assessed all heart failure patients who died between 1 July 2007 and 31 December 2020 for evidence-based treatments. The proportion on the respective treatment at the time of death was examined by year of death using binomial regression. Looking back in time, treatment discontinuation rates were estimated using Poisson regression on time-split data. Combining these models, the proportion on each medication was estimated up to 5\u2009years prior to death. A total of 364\u2009480 patients died with heart failure during the study period. Half were women, and the median (interquartile range) age at death was 86 (79\u201390). The use of all heart failure treatments decreased gradually closer to death, but the discontinuation rate of beta blockers decreased over time, resulting in an increasing proportion of patients on treatment at the time of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with heart failure, a changing pattern of medical treatment during the last years of life was observed, most notably with an increasing use of beta blockers. This may in part be due to a changing pattern of comorbidities over time, with an increase in e.g. hypertension and atrial fibrillation, but a decline in ischaemic heart disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3426","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T13:00:27Z","timestamp":1725109227000},"page":"2443-2450","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heart Failure Treatment in the Last Years of Life: A Nationwide Study of 364\u2009000 Individuals"],"prefix":"10.1093","volume":"26","author":[{"given":"Johan","family":"Sundstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Sence Research AB , Uppsala ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cars","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Sence Research AB , Uppsala ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-0614","authenticated-orcid":false,"given":"Daniel","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Department of Medicine, Norrt\u00e4lje Hospital (TioHundra AB) , Norrt\u00e4lje ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"2026010913045660100_ejhf3426-bib-0001","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913045660100_ejhf3426-bib-0002","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026010913045660100_ejhf3426-bib-0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913045660100_ejhf3426-bib-0004","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-023-02567-2","article-title":"Recent successes in heart failure treatment","volume":"29","author":"Lam","year":"2023","journal-title":"Nat Med"},{"key":"2026010913045660100_ejhf3426-bib-0005","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ehf2.13929","article-title":"Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction","volume":"9","author":"Girerd","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0006","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026010913045660100_ejhf3426-bib-0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026844","article-title":"Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction","volume":"12","author":"Kondo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026010913045660100_ejhf3426-bib-0008","first-page":"36","article-title":"Validity of heart failure diagnoses made in 2000\u20132012 in western Sweden","volume":"7","author":"Schaufelberger","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0009","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ejheart.2004.12.007","article-title":"The validity of a diagnosis of heart failure in a hospital discharge register","volume":"7","author":"Ingelsson","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.HYP.2.6.757","article-title":"Can simple clinical measurements detect patient noncompliance?","volume":"2","author":"Haynes","year":"1980","journal-title":"Hypertension"},{"key":"2026010913045660100_ejhf3426-bib-0011","doi-asserted-by":"crossref","DOI":"10.1201\/9781315370279","volume-title":"Generalized additive models: An introduction with R","author":"Wood","year":"2017","edition":"2nd ed."},{"key":"2026010913045660100_ejhf3426-bib-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i05","article-title":"Lexis: An R class for epidemiological studies with long-term follow-up","volume":"38","author":"Plummer","year":"2011","journal-title":"J Stat Softw"},{"key":"2026010913045660100_ejhf3426-bib-0013","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1016\/S2666-7568(21)00170-7","article-title":"Discontinuation of diabetes medication in the 10\u2009years before death in Denmark: A register-based study","volume":"2","author":"Kosjerina","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"2026010913045660100_ejhf3426-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026319","article-title":"Supporting the heterogeneous and evolving treatment preferences of patients with heart failure through collaborative home-based palliative care","volume":"11","author":"Campos","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026010913045660100_ejhf3426-bib-0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2026010913045660100_ejhf3426-bib-0016","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913045660100_ejhf3426-bib-0017","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913045660100_ejhf3426-bib-0018","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/ejhf.2831","article-title":"Health status across major subgroups of patients with heart failure and preserved ejection fraction","volume":"25","author":"Siddiqi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0019","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/ejhf.2965","article-title":"Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991\u20132016","volume":"25","author":"Docherty","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913045660100_ejhf3426-bib-0021","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2443\/65507876\/eurjhf_26_11_2443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2443\/65507876\/eurjhf_26_11_2443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:05:53Z","timestamp":1767981953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/11\/2443\/8328644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,8,31]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3426","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"2024-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}